IDEXX Laboratories, Inc. (IDXX): Price and Financial Metrics

IDEXX Laboratories, Inc. (IDXX): $584.47

3.94 (+0.68%)

POWR Rating

Component Grades














  • IDXX scores best on the Quality dimension, with a Quality rank ahead of 96.01% of US stocks.
  • The strongest trend for IDXX is in Quality, which has been heading up over the past 31 weeks.
  • IDXX's current lowest rank is in the Momentum metric (where it is better than 34.68% of US stocks).

IDXX Stock Summary

  • IDXX has a market capitalization of $48,325,135,396 -- more than approximately 94.77% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for IDXX is 4.07 -- better than 89.81% of US stocks.
  • The price/operating cash flow metric for Idexx Laboratories Inc is higher than 93.18% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to IDXX, based on their financial statements, market capitalization, and price volatility, are TEL, A, BAX, MNST, and ROST.
  • Visit IDXX's SEC page to see the company's official filings. To visit the company's web site, go to

IDXX Price Target

For more insight on analysts targets of IDXX, see our IDXX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $587.00 Average Broker Recommendation 1.45 (Moderate Buy)

IDXX Stock Price Chart Interactive Chart >

Price chart for IDXX

IDXX Price/Volume Stats

Current price $584.47 52-week high $584.52
Prev. close $580.53 52-week low $294.17
Day low $576.60 Volume 246,400
Day high $584.52 Avg. volume 420,916
50-day MA $536.68 Dividend yield N/A
200-day MA $477.09 Market Cap 49.84B

IDEXX Laboratories, Inc. (IDXX) Company Bio

IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company was founded in 1983 and is based in Westbrook, Maine.

IDXX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$584.47$243.11 -55%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Idexx Laboratories Inc. To summarize, we found that Idexx Laboratories Inc ranked in the 34th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Idexx Laboratories Inc ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Its equity weight surpasses that of 84.47% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than just 10.69% of the free cash flow producing stocks we're observing.
  • IDXX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 53.39% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as IDXX, try DXCM, JNJ, NUVA, QGEN, and GMED.

IDXX Latest News Stream

Event/Time News Detail
Loading, please wait...

IDXX Latest Social Stream

Loading social stream, please wait...

View Full IDXX Social Stream

Latest IDXX News From Around the Web

Below are the latest news stories about Idexx Laboratories Inc that investors may wish to consider to help them evaluate IDXX as an investment opportunity.

Idexx Stock Clears Key Benchmark Amid Strong Profit, Sales Growth; Expands Via Cloud Software Buyout

Idexx Laboratories sees its Relative Strength Rating move into the 80-plus level.

Investor''s Business Daily | June 11, 2021

Henry Schein (HSIC) Enhances Dental Practices With New Deal

Henry Schein's (HSIC) acquisition of majority stake in eAssist will enable it to offer best quality solutions to help dental practices operate efficiently and profitably.

Yahoo | June 11, 2021

Hologic (HOLX) Acessa Procedure Now Covered by Cigna Insurance

Hologic's (HOLX) Acessa procedure new coverage will further validate Laparoscopic Radiofrequency Ablation as a standard of care for uterine fibroids.

Yahoo | June 10, 2021

CVS Health (CVS) Deploys Time-Delay Safes in Georgia Pharmacies

CVS Health's (CVS) time-delay safes are anticipated to help reduce robbery incidents.

Yahoo | June 9, 2021

Up 100% in a Year, Can This Animal Health Stock Keep Climbing?

Not only has Heska stock doubled in a year, it has quintupled over the past five years, and it's a 20-bagger over the last decade. Why is this animal health stock flying so high?

Yahoo | June 9, 2021

Read More 'IDXX' Stories Here

IDXX Price Returns

1-mo 10.26%
3-mo 15.30%
6-mo 25.00%
1-year 93.00%
3-year 156.46%
5-year 556.78%
YTD 16.92%
2020 91.43%
2019 40.38%
2018 18.95%
2017 33.35%
2016 60.82%

Continue Researching IDXX

Here are a few links from around the web to help you further your research on Idexx Laboratories Inc's stock as an investment opportunity:

Idexx Laboratories Inc (IDXX) Stock Price | Nasdaq
Idexx Laboratories Inc (IDXX) Stock Quote, History and News - Yahoo Finance
Idexx Laboratories Inc (IDXX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8995 seconds.